Escalated ADT Falls Short in Men With High-Risk Features After Prostatectomy
(MedPage Today) -- SAN FRANCISCO -- Add-on hormone therapy plus an antiandrogen to salvage radiation and androgen deprivation therapy (ADT) did not boost survival outcomes in high-risk prostate cancer. In the FORMULA-509 trial, the addition...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news
More News: Cancer | Cancer & Oncology | Hematology | Hormonal Therapy | Hormones | Prostate Cancer | Prostatectomy